Smith E. et al. Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. Heart. 2020;106(9):691-697.
Why this study
Ergothioneine is the "mushroom antioxidant" the body hoards via a dedicated transporter, OCTN1. But before this paper no large human cohort had tested whether blood ergothioneine predicts real outcomes rather than just "health benefit" in vitro.
Methods
- Prospective Malmö Diet and Cancer cohort: 3236 participants free of CVD and diabetes at baseline.
- 112 plasma metabolites measured by LC-MS; searched for metabolites tied to the "health conscious food pattern" (HCFP).
- Median follow-up — 21.4 years; endpoints: coronary disease, diabetes, cardiovascular and all-cause mortality.
Findings
Ergothioneine was the metabolite most strongly connected to the healthy-eating pattern — and predicted outcomes (HR per 1 SD increment):
- Coronary disease: HR 0.85 (−15% risk)
- Cardiovascular mortality: HR 0.79 (−21%)
- All-cause mortality: HR 0.86 (−14%)
Limitations
- Observational — association is not causation; ergothioneine may be a marker of an overall "mushroom/fish/vegetable" diet.
- The metabolite was measured once at baseline.
Why it matters
This is the fourth branch of ergothioneine on the site: cancer (Ba meta-analysis), MCI (Feng), plasma prediction of cognitive decline (Wu) — and now mortality/CVD (Smith). Malmö's uniqueness — the longest follow-up and largest n of all our ergothioneine cards.